文献速递急性肾损伤遗传性与小管间质肾病

维莫非尼肾毒性由脱靶抑制亚铁螯合酶驱动

Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.
PubMed 文献 · Kidney Int · 2021-09-15

研究通过细胞培养和小鼠模型探究BRAF抑制剂维莫非尼的肾毒性机制。临床相关浓度下维莫非尼诱导肾小管上皮细胞死亡,小鼠每日给药两周引起中度急性肾损伤。肾小管上皮细胞特异性BRAF基因缺失不影响肾功能或损伤严重度,而抑制亚铁螯合酶参与肾毒性,过表达保护细胞,敲低增加敏感性。

要点

  • 维莫非尼肾小管毒性不依赖BRAF抑制
  • 脱靶抑制亚铁螯合酶部分介导肾毒性
  • 亚铁螯合酶过表达可保护肾小管上皮细胞

核心结论

  • 维莫非尼相关肾小管上皮细胞功能障碍和肾毒性不依赖BRAF,部分由脱靶抑制亚铁螯合酶引起。

研究设计与样本

  • 研究采用细胞培养和小鼠模型探究维莫非尼肾毒性机制。
  • 小鼠接受每日维莫非尼治疗两周。

主要发现

  • 临床相关浓度维莫非尼诱导转化和原代小鼠及人肾小管上皮细胞死亡。
  • 小鼠每日维莫非尼治疗两周引起中度急性肾损伤,伴肾小管上皮细胞损伤的组织病理学特征。
  • 肾小管上皮细胞特异性BRAF基因缺失不影响正常肾功能或维莫非尼相关肾损伤严重度。
  • 抑制亚铁螯合酶参与维莫非尼肾毒性,过表达保护肾小管上皮细胞,敲低增加敏感性。

临床怎么用

  • 接受维莫非尼治疗的患者应监测肾功能和肾小管损伤标志物。
  • 亚铁螯合酶抑制可能是防治维莫非尼肾毒性的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A multitude of disease and therapy related factors drive the frequent development of kidney disorders in cancer patients. Along with chemotherapy, the newer targeted therapeutics can also cause kidney dysfunction through on and off-target mechanisms. Interestingly, among the small molecule inhibitors approved for the treatment of cancers that harbor BRAF-kinase activating mutations, vemurafenib can trigger tubular damage and acute kidney injury. BRAF is a proto-oncogene involved in cell growth. To investigate the underlying mechanisms, we developed cell culture and mouse models of vemurafenib kidney toxicity. At clinically relevant concentrations vemurafenib induces cell-death in transformed and primary mouse and human kidney tubular epithelial cells. In mice, two weeks of daily vemurafenib treatment causes moderate acute kidney injury with histopathological characteristics of kidney tubular epithelial cells injury. Importantly, kidney tubular epithelial cell-specific BRAF gene deletion did not influence kidney function under normal conditions or alter the severity of vemurafenib-associated kidney impairment. Instead, we found that inhibition of ferrochelatase, an enzyme involved in heme biosynthesis contributes to vemurafenib kidney toxicity. Ferrochelatase overexpression protected kidney tubular epithelial cells and conversely ferrochelatase knockdown increased the sensitivity to vemurafenib-induced kidney toxicity. Thus, our studies suggest that vemurafenib-associated kidney tubular epithelial cell dysfunction and kidney toxicity is BRAF-independent and caused, in part, by off-target ferrochelatase inhibition.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Bai Y, Kim JY, Bisunke B, et al. Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. Kidney Int. 2021. PMID: 34534550. doi:10.1016/j.kint.2021.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。